Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Ord Shs RLFTF

Healthcare Biotechnology
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of... see more

Recent & Breaking News (OTCQB:RLFTF)

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders

ACCESS Newswire June 20, 2023

RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement

ACCESS Newswire June 16, 2023

RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

ACCESS Newswire May 26, 2023

Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

ACCESS Newswire May 15, 2023

Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission

ACCESS Newswire May 12, 2023

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

ACCESS Newswire May 3, 2023

Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule

ACCESS Newswire May 1, 2023

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

ACCESS Newswire April 28, 2023

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100

ACCESS Newswire April 17, 2023

Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update

ACCESS Newswire April 14, 2023

Relief Therapeutics Announces Executive Leadership Team Change

ACCESS Newswire April 5, 2023

Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders

ACCESS Newswire April 4, 2023

Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board

ACCESS Newswire April 3, 2023

Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

ACCESS Newswire March 22, 2023

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

ACCESS Newswire March 17, 2023

Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

ACCESS Newswire March 16, 2023

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA

ACCESS Newswire March 15, 2023

Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars

ACCESS Newswire February 28, 2023

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa

ACCESS Newswire February 14, 2023

Relief Therapeutics Provides an Update on its Financing Strategy

ACCESS Newswire February 8, 2023